Study guide
3.12 Prenatal Screening (NIPT, Serum Markers)
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
3.12 Prenatal Screening (NIPT, Serum Markers)
Key Takeaways Explain This Topic AI
NIPT analyzes cell-free DNA (cfDNA) in maternal plasma—largely placental in origin—to screen for common fetal aneuploidies; it is screening, not diagnostic
Test performance concepts: high sensitivity/specificity for trisomy 21 in validated populations, but positive predictive value depends on prevalence (maternal age/prior risk); fetal fraction critically affects reliability
False-positive or discordant NIPT results may stem from confined placental mosaicism, vanishing twin, maternal copy-number variation or mosaicism, and rarely maternal malignancy
Serum marker screens (first-trimester combined, quad screen) use analytes ± nuchal translucency to modify aneuploidy and, for AFP-based screens, open neural tube defect risk—also screening only
Screen-positive results require offer of genetic counseling and diagnostic confirmation (CVS/amnio); screen-negative results reduce but do not eliminate residual risk
Last updated: August 2026
3.12 Prenatal Screening (NIPT, Serum Markers)
Quick Answer: NIPT (cfDNA) screens maternal plasma for common aneuploidies using DNA that is largely placental . It is not diagnostic . Performance depends on fetal fraction and prior risk ( PPV ). Discordant positives can reflect CPM , vanishing twin , maternal CNV/mosaicism , or rarely maternal malignancy . Serum screens (combined first-trimester, quad ) also modify risk only—confirm screen-positives with diagnostic procedures when the patient wants certainty.
Domain 3C expects crisp separation of screening vs diagnosis , correct counseling after a “positive NIPT,” and recognition of why cfDNA can disagree with the fetus.
Screening vs Diagnosis (Non-Negotiable Frame)
Screening (NIPT, serum markers, many ultrasound soft markers) Diagnosis (CVS, amniocentesis with chromosomal/molecular analysis)
Purpose Stratify probability Determine fetal genotype/karyotype (within test limits)
Result language High risk / low risk / positive / negative screen Presence/absence of tested abnormality (or mosaic/uncertain)
Next step after positive Offer diagnostic testing + counseling Clinical management and decision support
Exam trap: Telling a patient that NIPT “diagnosed Down syndrome.” Trisomy 21 on NIPT is a high-probability screen requiring confirmatory diagnostic testing before irreversible pregnancy decisions in standard counseling frameworks.
NIPT / cfDNA: Mechanism and Scope
Cell-free DNA in maternal blood includes maternal cfDNA plus placental trophoblast-derived DNA (often called “fetal fraction,” though the source is placental). Labs analyze counts or genotypes across chromosomes to detect over-/under-representation consistent with aneuploidy (commonly 21, 18, 13; sex chromosome aneuploidies and selected microdeletion panels vary by lab and indication).
Typical counseling points before draw:
What conditions are included vs excluded (e.g., many single-gene disorders are not covered by standard aneuploidy NIPT).
Possibility of no-call / low fetal fraction results, especially at earlier gestations, higher BMI, or certain aneuploidies.
Incidental detection of maternal chromosomal findings or, rarely, clues to maternal neoplasm.
Twin and vanishing-twin complexity.
Performance Concepts You Must Apply
Sensitivity / specificity describe how often the test correctly flags affected vs unaffected pregnancies in validation cohorts. For trisomy 21, published NIPT performance is generally excellent as a screen —but that is not the same as PPV.
Positive predictive value (PPV) = among screen-positives, the proportion truly affected. PPV falls when prevalence is low (e.g., young patient without other risk factors) even if sensitivity/specificity are high. Always contextualize a positive NIPT with prior risk (age, ultrasound, serum screen, personal/family history).
Negative predictive value (NPV) is typically high for common aneuploidies in general obstetric populations, which is why a low-risk NIPT is reassuring—but residual risk is not zero , and structural anomalies or conditions outside the panel remain possible.
- Concept Counselor translation
- Fetal fraction Too low → no-call or unreliable result; redraw or alternative testing
- Sensitivity Ability to detect true aneuploidy when present
- Specificity Ability to call screen-negative when euploid
- PPV “If positive, how likely is the fetus affected?” — prevalence-dependent
- NPV “If negative, how likely is the fetus unaffected for the screened condition?”
- Why NIPT Can Be Wrong: Biologic False Positives / Discordance
- Because cfDNA is placental-leaning , discordance with the fetus is expected biology—not merely “lab error.”
Mechanism What happens Counseling implication
Confined placental mosaicism (CPM) Aneuploid cell line in placenta but fetus euploid (or different) Diagnostic testing (preferably amnio reflecting fetal cells) may be discordant with NIPT
Vanishing twin cfDNA from a demised twin’s placenta persists False positive or sex discordance; obtain early ultrasound history
Maternal CNV or mosaicism Maternal chromosomal imbalance contributes to the cfDNA signal May need maternal diagnostic workup; fetus may be unaffected
Maternal malignancy (rare) Tumor cfDNA distorts genomic representation Multiple aneuploidies / non-reportable patterns may prompt oncology evaluation pathways
Technical / statistical borderline calls Low z-scores, low FF Redraw, alternate screen, or diagnostic offer
Worked scenario. A 28-year-old with unremarkable ultrasound has NIPT positive for monosomy X. PPV is lower than in a 40-year-old with cystic hygroma. Counsel prior-risk-adjusted interpretation, offer diagnostic confirmation, and mention CPM and maternal findings as reasons results can discord—without dismissing the finding.
Serum Marker Screening (Conceptual)
First-trimester combined screening typically uses pregnancy-associated plasma protein-A ( PAPP-A ), free β-hCG (or total hCG depending on protocol), and nuchal translucency (NT) ultrasound, sometimes with nasal bone or other markers, to produce aneuploidy risk figures.
Quad screen (second trimester) classically measures AFP , hCG , unconjugated estriol (uE3) , and inhibin A to modify risk for trisomy 21/18 and uses AFP for open neural tube defect risk assessment. Patterns (e.g., high AFP → NTD/ventral wall concern; low uE3 in certain contexts) are interpretive clues for MFM—not standalone diagnoses.
Screen Timing (typical) Strengths Limits
NT ± first-trimester serum ~11–13+ weeks Early risk assessment; NT detects some structural clues Screening only; NT requires quality ultrasound
Quad screen ~15–22 weeks (lab-dependent) Broad access; AFP for ONTD risk Lower aneuploidy detection than NIPT for common trisomies in many comparisons; dating errors affect analytes
NIPT/cfDNA From ~9–10 weeks (lab-dependent) High detection for common aneuploidies as screening Cost/access; placental source; panel limits; PPV issues
Sequential, contingent, or serum-integrated protocols exist historically; know that NIPT has shifted first-line aneuploidy screening in many settings, while serum AFP still contributes ONTD risk information that standard aneuploidy NIPT does not replace.
After a Screen-Positive or No-Call Result
Explain screening ≠ diagnosis; quote PPV language when available on the report.
Review ultrasound for anomalies that raise or lower post-test risk.
Offer diagnostic testing (CVS vs amnio—see 3.13) and genetic counseling time.
For no-call: discuss redraw vs proceed to diagnostic testing vs alternative screen, especially if high prior risk.
Avoid false reassurance from a subsequent normal ultrasound alone when NIPT was positive for aneuploidy—ultrasound can be normal in aneuploidy.
Master PPV + placental biology + screening-only language ; those three themes dominate NIPT board items.